Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: THR024
MIFTS: 63

Thrombosis

Categories: Blood diseases, Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Thrombosis

About this section

MalaCards integrated aliases for Thrombosis:

Name: Thrombosis 12 29 55 3 44 15 73
Thrombosis of Blood Vessel 73

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0060903
MeSH 44 D013927
Sources

Summaries for Thrombosis

About this section
Disease Ontology : 12 A vascular disease caused by the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system.

MalaCards based summary : Thrombosis, also known as thrombosis of blood vessel, is related to intracranial thrombosis and portal vein thrombosis. An important gene associated with Thrombosis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Heparin and Dalteparin have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and endothelial, and related phenotypes are Decreased viability and Decreased viability

CDC : 3 Many people who have or have had family members with hemophilia will ask that their baby boys get tested soon after birth.

Wikipedia : 76 Thrombosis (from Ancient Greek θρ�?μβ�?�?ι�? thrómbōsis "clotting�?�) is the formation of a blood clot... more...

Sources

Related Diseases for Thrombosis

About this section

Diseases related to Thrombosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1188)
# Related Disease Score Top Affiliating Genes
1 intracranial thrombosis 34.0 APOH F3 F5 SERPINC1 VWF
2 portal vein thrombosis 33.9 APOH F2 F5 JAK2 SELP SERPINC1
3 sagittal sinus thrombosis 33.9 F2 F3 F5 SERPINC1
4 coronary thrombosis 33.8 F3 GP1BA PLAT SERPINC1 SERPINE1 VWF
5 cerebral sinovenous thrombosis 33.6 APOH F2 F3 F5 PROS1
6 carotid artery thrombosis 33.6 F3 PLAT SELP SERPINE1
7 budd-chiari syndrome 33.2 APOH F2 F3 F5 JAK2 SERPINC1
8 thrombophilia due to thrombin defect 32.9 APOH F13A1 F2 F3 F5 PLAT
9 heparin-induced thrombocytopenia 32.8 F3 SERPINC1
10 antithrombin iii deficiency 32.6 APOH F2 F5 SERPINC1
11 post-thrombotic syndrome 32.5 F2 F5 SERPINC1 SERPINE1
12 shwartzman phenomenon 32.4 F3 SERPINA10
13 protein s deficiency 32.3 APOH F2 F3 F5 PROS1 SERPINC1
14 polycythemia vera 32.3 F5 JAK2 SELP THBD
15 homocysteinemia 32.2 F2 F5 SERPINC1
16 hepatic veno-occlusive disease 32.2 F3 PLAT SERPINC1 SERPINE1 THBD
17 protein c deficiency 32.2 F2 F5 F9 HRG PROC SERPINC1
18 dysfibrinogenemia 32.2 F13A1 F2 F5 PLAT SERPINC1 THBD
19 factor vii deficiency 32.2 F2 F3 F9
20 buerger disease 32.2 APOH F2 SERPINE1
21 antiphospholipid syndrome 32.0 APOH F2 F3 F5 PLAT SELP
22 catastrophic antiphospholipid syndrome 32.0 APOH F3 F5 PROC SERPINE1
23 thrombocytosis 32.0 F2 F3 JAK2 SELP SERPINC1
24 chronic venous insufficiency 32.0 PLAT SELP SERPINE1
25 thrombophilia due to activated protein c resistance 31.9 APOH F2 F3 F5 F9 PLAT
26 pulmonary embolism 31.9 APOH F2 F3 F5 F9 PLAT
27 thrombophilia 31.9 APOH F2 F3 F5 F9 HRG
28 factor v deficiency 31.8 F2 F3 F5 F9 TFPI VWF
29 essential thrombocythemia 31.7 F2 F3 GP1BA JAK2 SELP SERPINE1
30 plasminogen activator inhibitor-1 deficiency 31.7 PLAT SERPINE1
31 stroke, ischemic 30.9 APOH F2 F3 F5 PLAT SELP
32 may-thurner syndrome 30.8 APOH F5
33 vein disease 30.7 F2 F3 F5 PLAT PROC PROS1
34 portal hypertension 30.6 F2 JAK2 VWF
35 varicose veins 30.5 F2 F5 SERPINC1 VWF
36 vasculitis 30.5 APOH THBD VWF
37 thrombophlebitis 30.4 APOH F2 F5 PLAT SERPINC1 SERPINE1
38 acute myocardial infarction 30.4 F3 PLAT SELP SERPINC1 SERPINE1 VWF
39 behcet syndrome 30.3 APOH F5 JAK2 SERPINC1 THBD
40 myocardial infarction 30.3 F13A1 F2 F3 F5 GP1BA PLAT
41 pulmonary hypertension 30.3 F3 PLAT THBD VWF
42 atrial fibrillation 30.3 F2 PLAT SELP VWF
43 intracranial hypertension 30.3 APOH F2 F3 F5 SERPINC1 SERPINE1
44 endocarditis 30.3 APOH F2 PLAT SERPINC1
45 disseminated intravascular coagulation 30.3 F2 F3 F5 F9 PLAT SERPINC1
46 coronary artery anomaly 30.3 F2 F5 PLAT SELP SERPINE1
47 purpura 30.2 APOH F2 F3 PROC PROS1 SERPINC1
48 arteries, anomalies of 30.2 F3 PLAT SELP SERPINC1 SERPINE1 VWF
49 patent foramen ovale 30.1 APOH F13A1 F2 F5 PLAT SERPINC1
50 factor xii deficiency 30.1 APOH F3 F5 F9 SERPINC1

Graphical network of the top 20 diseases related to Thrombosis:



Diseases related to Thrombosis
Sources

Symptoms & Phenotypes for Thrombosis

About this section

GenomeRNAi Phenotypes related to Thrombosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-2 10.05 JAK2
2 Decreased viability GR00381-A-1 10.05 PLAT SERPINA10
3 Decreased viability GR00381-A-2 10.05 SERPINA10
4 Decreased viability GR00381-A-3 10.05 SERPINA10
5 Decreased viability GR00402-S-2 10.05 APOH CD55 F13A1 F2 F3 F5
6 no effect GR00402-S-1 9.62 APOH CD55 F13A1 F2 F3 F5

MGI Mouse Phenotypes related to Thrombosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 APOH F13A1 F2 F3 F5 F9
2 cardiovascular system MP:0005385 10.35 F13A1 F2 F3 F5 F9 PLAT
3 hematopoietic system MP:0005397 10.31 CD55 F13A1 F2 F3 F9 GP1BA
4 immune system MP:0005387 10.18 CD55 F2 F3 F9 JAK2 PLAT
5 embryo MP:0005380 10.11 F2 F3 F5 F9 JAK2 PROS1
6 mortality/aging MP:0010768 10.09 APOH F13A1 F2 F3 F5 F9
7 integument MP:0010771 10.02 F2 F3 F5 JAK2 PLAT PROS1
8 liver/biliary system MP:0005370 9.91 F5 F9 JAK2 PROC PROS1 SELP
9 nervous system MP:0003631 9.73 F2 F3 F5 PLAT PROC PROS1
10 respiratory system MP:0005388 9.23 F13A1 F2 F3 PLAT PROC SELP
Sources

Drugs & Therapeutics for Thrombosis

About this section

Drugs for Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1045)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6 772 46507594
2
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6
3
Acenocoumarol Approved, Investigational Phase 4,Phase 3,Not Applicable 152-72-7 9052 54676537
4
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6 772
5
Phenprocoumon Approved, Investigational Phase 4,Phase 3,Phase 2 435-97-2 54680692 9908
6
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 128270-60-0 16129704
7
Tirofiban Approved Phase 4,Phase 3,Phase 2,Not Applicable 144494-65-5 60947
8
Tenecteplase Approved Phase 4,Phase 3,Phase 2,Phase 1 191588-94-0
9
Nadroparin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable
10 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11
Warfarin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81-81-2 6691 54678486
12
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
13
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 113665-84-2, 120202-66-6 60606
14
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55142-85-3 5472
15
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 274693-27-5 9871419
16
Abciximab Approved Phase 4,Phase 3,Phase 2,Not Applicable 143653-53-6
17
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
18
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19
Phenobarbital Approved, Investigational Phase 4,Phase 3,Not Applicable 50-06-6 4763
20
Tranylcypromine Approved, Investigational Phase 4,Phase 3 155-09-9 441233
21
Rivaroxaban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 366789-02-8
22
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1197-18-8 5526
23
Alprostadil Approved, Investigational Phase 4,Phase 3,Phase 2 745-65-3 149351 5280723
24
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 69-72-7 338
25
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 73590-58-6 4594
26
Pantoprazole Approved Phase 4,Phase 3,Phase 1,Not Applicable 102625-70-7 4679
27
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
28
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
29
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
30
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-28-2 5757
31
Norethindrone Approved Phase 4,Not Applicable 68-22-4 6230
32
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Not Applicable 28014-46-2
33 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 979-32-8
34
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
35
Coal tar Approved Phase 4,Phase 1,Not Applicable 8007-45-2
36
Chromium Approved Phase 4,Phase 2,Phase 3,Not Applicable 7440-47-3 27668
37
Cobalt Approved, Experimental Phase 4,Phase 2,Phase 3,Not Applicable 7440-48-4 104729
38
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73963-72-1 2754
39
Hydroxocobalamin Approved Phase 4,Phase 3,Not Applicable 13422-51-0 11953898 44475014
40
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
41
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Not Applicable 13422-55-4
42
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7439-89-6 23925
43
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
44 fluindione Approved, Investigational Phase 4,Phase 3,Not Applicable 957-56-2
45
Phytonadione Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 84-80-0 4812 5284607
46
Nitric Oxide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 10102-43-9 145068
47
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 55-56-1 2713 9552079
48 Nutmeg Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49
Glucosamine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 3416-24-8 439213
50
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 61825-94-3 43805 6857599 5310940 9887054

Interventional clinical trials:

(show top 50) (show all 5212)
# Name Status NCT ID Phase Drugs
1 Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis Unknown status NCT02959801 Phase 4
2 Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis Unknown status NCT00450645 Phase 4 low molecular weight heparin
3 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC) Unknown status NCT02826200 Phase 4 Acenocoumarol
4 Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis Unknown status NCT01252420 Phase 4 Enoxaparin
5 Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
6 Rosuvastatin for Preventing Deep Vein Thrombosis Unknown status NCT01021488 Phase 4 Rosuvastatin 20mg/d for 14days;enoxaparin only
7 Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty Unknown status NCT02592694 Phase 4 cocktail
8 Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF Unknown status NCT02256683 Phase 4 Dabigatran etexilate;Phenprocoumon
9 Safety and Efficacy Study of OmniWave Endovascular System to Treat Deep Vein Thrombosis Unknown status NCT00640731 Phase 4
10 The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis：A Multicenter RCT Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
11 Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients Unknown status NCT02639143 Phase 4 ticagrelor;Clopidogrel
12 The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
13 Re-STOP DVT: Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users Unknown status NCT01063426 Phase 4 High dose Atorvastatin+enoxaparin;Enoxaparin
14 Thrombus Aspiration for OcLuded Coronary Artery Enhanced With Distal Injection Of Abciximab Unknown status NCT01383785 Phase 4
15 Thrombus Aspiration in Patients With STEMI Unknown status NCT02606435 Phase 4
16 Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Non-ST-elevation Myocardial Infarction Study Unknown status NCT01013038 Phase 4
17 Dissecting the Role of Distal Embolization of Athero-thrombotic Material in Primary PCI: the ThrombOticBurden and mIcrovAscularobStruction (TOBIAS) Study. Unknown status NCT01914055 Phase 4
18 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
19 Antiaggregation in Primary Prevention of Vascular Access for Hemodialysis Unknown status NCT02055131 Phase 4 aspirin
20 Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA Unknown status NCT01670474 Phase 4 rt-PA (2mg/2mL) actilysis;rt-PA
21 Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery Unknown status NCT00983112 Phase 4 Human Fibrinogen and human thrombin (Evicel);Sodium Chlorure (Physiological saline)
22 Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside) Unknown status NCT00963781 Phase 4 Reduced duration (6 months) DAPT
23 Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients. Unknown status NCT01970280 Phase 4 Enoxaparin
24 Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty Unknown status NCT02453802 Phase 4 Tranexamic Acid 5%,5ml/amp;Tranexamic Acid 5%,5ml/amp;rivaroxaban (10mg);0.9% Normal Saline;0.9% Normal Saline
25 Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction Unknown status NCT01499407 Phase 4 Abciximab
26 Efficacy of Thrombosuction in Primary Percutaneous Coronary Intervention of Acute Myocardial Infarction Unknown status NCT01156662 Phase 4
27 PPARGC1β and CNTN4 Genotype Aspirin Study Unknown status NCT02970604 Phase 4 Aspirin
28 The Use of Prostaglandin E1 in Head and Neck Microsurgery Unknown status NCT00733434 Phase 4 Prostaglandin E1
29 Randomised Controlled Trial of Needle Free Access Devices in Preventing Hemodialysis Blood Stream Infection Unknown status NCT01082770 Phase 4
30 Anticoagulation in Stent Intervention Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
31 DEDICA (Dose of HEparin During Coronary Angioplasty) Trial Unknown status NCT01694459 Phase 4 Low-dose heparin;Standard dose heparin
32 Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN) Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
33 Late Incomplete Stent Apposition Evaluation II: Comparison Between Polimer-based and No-polimer Stent System. IVUS Based Study Unknown status NCT01375855 Phase 4
34 Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI Unknown status NCT01781715 Phase 4
35 Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
36 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
37 Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy Unknown status NCT02264743 Phase 4 Femoston Conti;EVOREL® CONTI
38 Cost Effectiveness Analysis In Patients With Heart Valve Prosthesis Unknown status NCT02022527 Phase 4 Acetyl Salicylic Acid;Warfarin;Placebo (for Aspirin)
39 EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography Unknown status NCT01371279 Phase 4
40 Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation Unknown status NCT00776633 Phase 4 aspirin;clopidogrel;oral anticoagulation
41 Intravascular ULTrasound Guided Versus Conventional Angiography Guided Strategy to Deploy Zotarolimus and Everolimus Eluting Third Generation Stents in the Long Coronary Artery Lesions: ULTRA-ZET Trial Unknown status NCT01979744 Phase 4
42 Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction Unknown status NCT00976092 Phase 4 Prasugrel;Bivalirudin;Clopidogrel;Heparin
43 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
44 Twelve vs 24 Months of Dual Antiplatelet Therapy in Patients With Coronary Revascularization for In-stent Restenosis Unknown status NCT02402491 Phase 4 12 months of P2Y12 receptor antagonist;24 months of P2Y12 receptor antagonist;Aspirin
45 Local Thrombolytics Before Thrombectomy in STEMI Unknown status NCT01568931 Phase 4 Urokinase;Saline
46 Reversal of the Antithrombotic Action of New Oral Anticoagulants Unknown status NCT01478282 Phase 4 Rivaroxaban;Dabigatran
47 Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI Unknown status NCT02012140 Phase 4 ticagrelor
48 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
49 Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome Unknown status NCT01951001 Phase 4 Prasugrel
50 Safety and Effectiveness of the Coronary Momo Stent Unknown status NCT01535625 Phase 4

Search NIH Clinical Center for Thrombosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: thrombosis

Sources

Genetic Tests for Thrombosis

About this section

Genetic tests related to Thrombosis:

# Genetic test Affiliating Genes
1 Thrombosis 29
Sources

Anatomical Context for Thrombosis

About this section

MalaCards organs/tissues related to Thrombosis:

41
Liver, Heart, Endothelial, Testes, Brain, Lung, Bone
Sources

Publications for Thrombosis

About this section

Articles related to Thrombosis:

(show top 50) (show all 10663)
# Title Authors Year
1
Development of a dural arteriovenous fistula subsequent to cerebral venous thrombosis by venous hypertension. ( 30555948 )
2019
2
Qualitative protein C deficiency due to PROC c.577_579delAAG mutation not detected by chromogenic assays: A case of intractable cerebral sinovenous thrombosis. ( 30255615 )
2019
3
Update on pathological platelet activation in coronary thrombosis. ( 30317596 )
2019
4
Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis. ( 30256409 )
2019
5
Retrospective study of the incidence of portal vein thrombosis after splenectomy in hematological disorders: Risk factors and clinical presentation. ( 30293687 )
2019
6
Characterization of Malignant Portal Vein Thrombosis with Contrast-Enhanced Ultrasonography. ( 30366607 )
2019
7
Percutaneous extrahepatic splenomeso-caval shunt creation in a patient with portal vein thrombosis after Whipple procedure. ( 30445372 )
2019
8
Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. ( 30450634 )
2019
9
A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. ( 30188408 )
2019
10
Clopidogrel pharmacogenetics: associations between genotype and stent thrombosis risk in patients with stent placement. ( 30531616 )
2019
11
Corrigendum to "Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation" [Biochim. Biophys. Acta, 1862 (2016) 1182-1190]. ( 30340914 )
2019
12
Radiation- and contrast medium-free catheter-directed thrombolysis for early pregnancy-related massive iliocaval deep venous thrombosis. ( 30385135 )
2019
13
Post-traumatic superior mesenteric venous thrombosis with subsequent extension to the portal vein. ( 30405866 )
2019
14
Relationship between genetic polymorphism of MTHFR C677T and lower extremities deep venous thrombosis. ( 30303041 )
2019
15
Thrombosis of the spleno-mesentiric portal axis following laparoscopic sleeve gastrectomy: A rare case report. ( 29438854 )
2018
16
Spontaneous intracranial hypotension complicated by cerebral venous thrombosis. ( 29955241 )
2018
17
Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis. ( 29958825 )
2018
18
Late diagnosis of homocystinuria in an adult after extensive cerebral venous thrombosis. ( 29175875 )
2018
19
Response by Liberman et al to Letter Regarding Article, "Misdiagnosis of Cerebral Vein Thrombosis in the Emergency Department". ( 29976577 )
2018
20
Regenerative nodular hyperplasia, portal vein thrombosis and primary myelofibrosis: An unusual triple association. ( 29368941 )
2018
21
Locked-in Syndrome and<sup>18</sup>F-fluorodeoxyglucose-positron Emission Tomography/Computed Tomography: Observations from a Case of Basilar Artery Thrombosis. ( 29430121 )
2018
22
Predicting Post-Thrombotic Syndrome with Ultrasonographic Follow-Up after Deep Vein Thrombosis: A Systematic Review and Meta-Analysis. ( 29972864 )
2018
23
Methylenetetrahydrofolate Reductase Gene Polymorphism (C677T) as a Risk Factor for Arterial Thrombosis in Georgian Patients. ( 29439641 )
2018
24
rLj-RGD3, a novel recombinant toxin protein from Lampetra japonica, prevents coronary thrombosis-induced acute myocardial infarction by inhibiting platelet functions in rats. ( 29407168 )
2018
25
Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: Not Only Recanalize the PortalA Vein. ( 29351835 )
2018
26
Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness &amp;amp; Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study. ( 29934383 )
2018
27
Serial long term follow up of a medically managed aortic prosthetic valve thrombosis. ( 29452310 )
2018
28
Neonatal cerebral sinovenous thrombosis: the anticoagulation debate. ( 29675894 )
2018
29
Adalimumab-based treatment versus DMARDs for venous thrombosis in BehAset syndrome. A retrospective study of 70 patients with vascular involvement. ( 29676522 )
2018
30
A case of portal vein thrombosis caused by blunt abdominal trauma in a patient with low protein C activity. ( 29923164 )
2018
31
Thrombosis and compartment syndrome requiring fasciotomy: Complications of internal iliac artery balloon catheters for morbidly adherent placenta. ( 29902690 )
2018
32
Prevention of recurrent venous thrombosis and post-thrombotic syndrome. ( 29795059 )
2018
33
Beneficial effect of combined spironolactone and quinapril treatment on thrombosis and hemostasis in 2K1C hypertensive rats. ( 29980144 )
2018
34
Congenital Thrombophilia in Patients With Superior Mesenteric Venous Thrombosis or Portal Vein Thrombosis. ( 29747524 )
2018
35
Portal Vein Thrombosis: Imaging the Spectrum of Disease With an Emphasis on MRI Features. ( 29792748 )
2018
36
Sticky Platelet Syndrome: An Unrecognized Cause of Acute Thrombosis and Graft Loss. ( 29850310 )
2018
37
Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. ( 28659045 )
2018
38
Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP). ( 29980524 )
2018
39
Liver Atrophy and Regeneration in Non-Cirrhotic Portal Vein Thrombosis: Effect of Surgical Shunts. ( 29377486 )
2018
40
Otogenic lateral sinus thrombosis in children: proposal of an experience-based treatment flowchart. ( 29948264 )
2018
41
Aneurysm of the inferior vena cava with thrombosis. ( 29445486 )
2018
42
Letter by Zhao et al Regarding Article, &amp;quot;Misdiagnosis of Cerebral Vein Thrombosis in the Emergency Department&amp;quot;. ( 29976578 )
2018
43
Serious Coronary Thrombosis and Pulmonary Artery Thrombosis Revealing BehAset's Disease. ( 29900996 )
2018
44
Optical Coherence Tomography for Guiding Plaque Stabilization in a Patient With Myocardial Infarction and Massive Coronary Thrombosis. ( 29958180 )
2018
45
Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation. ( 29903887 )
2018
46
Conservative management of neonatal cerebral sinovenous thrombosis with coexisting thrombophilia. ( 29708897 )
2018
47
Can thrombophilia predict recurrent catheter-related deep vein thrombosis in children? ( 29724900 )
2018
48
May-Thurner Syndrome Presenting as Acute Unexplained Deep Venous Thrombosis. ( 29793013 )
2018
49
Superior sagittal sinus thrombosis in a case of Mixed Connective Tissue Disease. ( 29848537 )
2018
50
Bland or tumor pulmonary artery stump thrombosis? ( 29448832 )
2018
Sources

Variations for Thrombosis

About this section
Sources

Expression for Thrombosis

About this section
Search GEO for disease gene expression data for Thrombosis.
Sources

Pathways for Thrombosis

About this section

Pathways related to Thrombosis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 13.19 APOH F13A1 F2 F3 F5 F9
2
Collagen chain trimerization 66
Show member pathways
 12.68 F13A1 F2 F3 F5 F9 PROC
3
Cell surface interactions at the vascular wall 66
Show member pathways
 12.05 F2 PROC PROS1 SELP THBD
4
Complement and coagulation cascades 1 37
11.94 CD55 F13A1 F2 F3 F5 F9
5
Gamma carboxylation, hypusine formation and arylsulfatase activation 66
Show member pathways
 11.79 F2 F9 PROC PROS1
6
AGE-RAGE signaling pathway in diabetic complications 37
11.73 F3 JAK2 SERPINE1 THBD
7
Integrin alphaIIb beta3 signaling 66
Show member pathways
 11.69 F2 GP1BA VWF
8
Formation of Fibrin Clot (Clotting Cascade) 66
Show member pathways
 11.67 F13A1 F2 F3 F5 F9 GP1BA
9
amb2 Integrin signaling 1
11.33 GP1BA PLAT SELP
10
Warfarin Pathway, Pharmacodynamics 61
10.8 F2 F9 PROC PROS1
11
Dissolution of Fibrin Clot 66
10.66 HRG PLAT SERPINE1
12
Platelet Adhesion to exposed collagen 66
10.62 GP1BA VWF
13
GP1b-IX-V activation signalling 66
10.49 GP1BA VWF
Sources

GO Terms for Thrombosis

About this section

Cellular components related to Thrombosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.97 APOH CD55 F3 GP1BA HRG PLAT
2 endoplasmic reticulum lumen GO:0005788 9.88 F2 F5 F9 PROC SERPINA10 SERPINC1
3 collagen-containing extracellular matrix GO:0062023 9.86 APOH F13A1 F3 HRG PLAT SERPINC1
4 extracellular region GO:0005576 9.86 APOH CD55 F13A1 F2 F3 F5
5 blood microparticle GO:0072562 9.83 F13A1 F2 HRG PROS1 SERPINC1
6 Golgi lumen GO:0005796 9.76 F2 F9 PROC PROS1
7 platelet alpha granule lumen GO:0031093 9.63 F13A1 F5 HRG PROS1 SERPINE1 VWF
8 extracellular space GO:0005615 9.5 APOH F2 F3 F5 F9 GP1BA
9 platelet alpha granule GO:0031091 9.49 F5 VWF
10 plasma membrane GO:0005886 10.32 CD55 F2 F3 F5 F9 GP1BA
11 extracellular exosome GO:0070062 10.1 APOH CD55 F2 F9 GP1BA HRG

Biological processes related to Thrombosis according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 ER to Golgi vesicle-mediated transport GO:0006888 9.95 CD55 F2 F5 F9 PROC PROS1
2 negative regulation of endopeptidase activity GO:0010951 9.93 HRG PROS1 SERPINA10 SERPINC1 SERPINE1 TFPI
3 platelet degranulation GO:0002576 9.92 APOH F13A1 F5 HRG PROS1 SELP
4 cellular protein metabolic process GO:0044267 9.91 F2 F5 PROC SERPINA10 SERPINC1
5 response to lipopolysaccharide GO:0032496 9.86 JAK2 SELP TFPI THBD
6 blood coagulation GO:0007596 9.86 F13A1 F2 F3 F5 F9 GP1BA
7 negative regulation of peptidase activity GO:0010466 9.84 SERPINA10 SERPINC1 SERPINE1 TFPI
8 platelet activation GO:0030168 9.83 F2 GP1BA HRG VWF
9 blood coagulation, intrinsic pathway GO:0007597 9.83 APOH F2 F9 GP1BA VWF
10 regulation of blood coagulation GO:0030193 9.8 APOH F2 GP1BA HRG SERPINC1
11 regulation of complement activation GO:0030449 9.77 CD55 F2 PROS1
12 negative regulation of fibrinolysis GO:0051918 9.77 APOH F2 HRG SERPINE1 THBD
13 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.76 F2 JAK2 SELP
14 fibrinolysis GO:0042730 9.73 F2 GP1BA HRG PLAT PROS1 SERPINE1
15 positive regulation of blood coagulation GO:0030194 9.67 APOH F2